Share chart Oncolytics Biotech Inc.
Extended chart
Simple chart
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., биофармацевтическая компания, находящаяся на стадии разработки, специализируется на открытии и разработке фармацевтических продуктов для лечения рака. Компания разрабатывает пелареореп, иммунотерапевтический препарат для внутривенного введения, который находится на третьей фазе клинических испытаний для лечения метастатического рака молочной железы с положительным по рецепторам гормонов/отрицательным к эпидермальному фактору роста 2 человека и распространенной/метастатической аденокарциномы протоков поджелудочной железы. Oncolytics Biotech Inc. more details| IPO date | 1999-11-08 |
|---|---|
| ISIN | CA6823108759 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | cad |
| Сайт | https://www.oncolyticsbiotech.com |
| Цена ао | 0.7139 |
| Change price per day: | -3.1% (0.6842) |
|---|---|
| Change price per week: | -8.63% (0.7256) |
| Change price per month: | -8.93% (0.728) |
| Change price per 3 month: | -28.73% (0.9302) |
| Change price per half year: | -34.36% (1.01) |
| Change price per year: | -27.93% (0.92) |
| Change price per 3 year: | -61% (1.7) |
| Change price per 5 year: | -76.65% (2.84) |
| Change price per 10 year: | -0% (0.663) |
| Change price per year to date: | -31.65% (0.97) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| International Assets Investment Management, LLC | 194963 | 0.27 |
| Renaissance Technologies, LLC | 129856 | 0.18 |
| Morgan Stanley | 106985 | 0.15 |
| Citadel Advisors Llc | 87858 | 0.12 |
| BNP Paribas Arbitrage, SNC | 68320 | 0.09 |
| Cibc World Markets, Inc. | 61081 | 0.08 |
| Royal Bank of Canada | 53656 | 0.07 |
| Long Focus Capital Management, LLC | 40000 | 0.06 |
| Geode Capital Management, LLC | 34659 | 0.05 |
| Dimensional Fund Advisors LP | 33485 | 0.05 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Matthew C. Coffey M.B.A., Ph.D. | President, CEO & Director (Leave of Absence) | 798.1k | |
| Mr. Kirk J. Look C.A., CA | Chief Financial Officer | 557.75k | |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer | 614.38k | |
| Ms. Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development | 423.7k | |
| Jon Patton | Director of Investor Relations & Communication | N/A | |
| Mr. Wayne F. Pisano M.B.A. | Interim CEO & Chairman of the Board | 1955 (70 years) | |
| Ms. Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations | ||
| Mr. John Mark Lievonen B.B.A., F.C.A., FCPA, LLD, M.B.A. | Consultant |
Address: Canada, Calgary, 322 11th Avenue SW - open in Google maps, open in Yandex maps
Website: https://www.oncolyticsbiotech.com
Website: https://www.oncolyticsbiotech.com
